Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline
· pulse2.com · popularity 16/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at pulse2.com →
Summary
Dren Bio has closed an oversubscribed $350 million private financing to advance its lead antibody therapy dibotatug toward regulatory submission and commercialization while expanding its broader oncology and autoimmune pipeline. The financing was co-led by Juvia Group and Lightspeed Venture Partners. New investors included Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed. The post Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 19.